Shanghai Escugen Biotechnology Co., Ltd

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus	Skin and Connective Tissue Diseases, autoimmune disease, connective tissue disorder, immune system disorder, systemic lupus erythematosus	Not yet recruiting	Phase 2	2026-08-12	NCT07760155
A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Primary Sjogren Syndrome	Primary Sjögren Syndrome	Not yet recruiting	Phase 2	2026-02-03	NCT07375524
Study of ESG406 in Adults With Solid Tumors	Locally Advanced/Metastatic Solid Tumors	Recruiting	Phase 1	2025-09-12	NCT06979674
A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia	Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, autoimmune disease, blood coagulation disease, blood platelet disease, hematologic disorder, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy	Recruiting	Phase 1 / Phase 2	2025-05-16	NCT06853444

Clinical trials